Why the study?
Placebo-controlled RCTs of SGLT-2 inhibitors across ejection fraction ranges were powered for composite outcomes rather than individual clinical endpoints such as mortality.
Do SGLT-2 inhibitors reduce all-cause mortality, cardiovascular mortality, and heart failure hospitalizations in patients with heart failure?
Do SGLT-2 inhibitors reduce all-cause mortality, cardiovascular mortality, and heart failure hospitalizations in patients with heart failure?
SGLT-2 inhibitors significantly reduce cardiovascular mortality and heart failure hospitalizations in patients with heart failure, demonstrating a consistent class effect.
Answers are grounded in this paper and cite their sources.
SGLT2 inhibitors reduce mortality and HF hospitalizations across HF phenotypes; reinforces RCT evidence for broad use regardless of ejection fraction.
AIMS: Sodium-glucose cotransporter 2 (SGLT-2) inhibitors have now been evaluated for the treatment of heart failure in several placebo-controlled randomized controlled trials (RCTs) across various ejection fraction ranges, but these trials were powered for composite outcomes rather than individual clinical endpoints. We therefore performed a meta-analysis to assess their safety and efficacy on all-cause mortality, cardiovascular mortality, and heart failure hospitalizations. METHODS AND RESULTS: We performed a prospectively registered random-effects meta-analysis of all RCTs comparing SGLT-2 inhibitors to placebo in patients with heart failure. The pre-specified primary endpoint was all-cause mortality. Secondary endpoints included cardiovascular mortality, heart failure hospitalizations, and the composite of cardiovascular mortality or heart failure hospitalization. Four trials with 15 684 patients were eligible. The SGLT-2 inhibitor tested was empagliflozin in two trials, dapagliflozin in one trial, and sotagliflozin in one trial. The weighted-mean follow-up was 20.0 months. The hazard ratio (HR) for all-cause mortality was 0.91, 95% confidence interval (CI) 0.82-1.01, P = 0.071. There was a 12% reduction in cardiovascular mortality (HR 0.88, 95% CI 0.79 to 0.97, P = 0.012), and a 30% reduction in heart failure hospitalization (HR 0.70, 95% CI 0.64 to 0.77, P < 0.001). CONCLUSION: SGLT-2 inhibitors significantly reduced cardiovascular mortality and heart failure hospitalizations in patients with heart failure. The effect appears consistent across three drugs studied in four trials. SGLT-2 inhibitors should become standard care for patients with heart failure.
No takes yet. Share an insight, caveat, or question.
Ahmad et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: